ANTI-PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODY MOLECULES, ENCODING POLYNUCLEOTIDES, AND METHODS OF USE

Provided herein are anti-Programmed Death-Ligand (PD-L1) antibodies, antigen-binding fragments thereof, multispecific antibodies and encoding polynucleotides. Also provided are PD-L1-targeted phthalocyanine dye conjugates, compositions and articles of manufacture containing the conjugates, and metho...

Full description

Saved in:
Bibliographic Details
Main Authors SUSLOV, Nikolai, STEINIGER, Sebastian, HOEY, Robert J, TEPLYAKOV, Alexey, THORNE, Amy, LAPETODA, Jason
Format Patent
LanguageEnglish
French
German
Published 25.12.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided herein are anti-Programmed Death-Ligand (PD-L1) antibodies, antigen-binding fragments thereof, multispecific antibodies and encoding polynucleotides. Also provided are PD-L1-targeted phthalocyanine dye conjugates, compositions and articles of manufacture containing the conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the anti-PD-L1 antibodies, fragments, and conjugates specifically bind to human PD-L1. Among the anti-PD-L1 antibodies are human antibodies and humanized antibodies. Also provided are methods and uses employing the provided anti-PD-L1 antibodies, antigen-binding fragments, and conjugates such for treatment of human patients.
Bibliography:Application Number: EP20230711646